The shifting paradigm in the treatment of type 2 diabetes mellitus—A cardiologist's perspective

In patients with diabetes mellitus, cardiovascular (CV) disease is the leading cause of morbidity and mortality. A multitude of contemporary antidiabetic agents presents different CV safety profiles. Metformin forms the cornerstone agent to reduce CV events. Newer agents, such as glucagon‐like pepti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cardiology (Mahwah, N.J.) N.J.), 2017-11, Vol.40 (11), p.970-973
Hauptverfasser:	Fatima, Saeeda, Jameel, Ayesha, Ayesha, FNU, Menzies, Dhananjai J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidiabetics Attitude of Health Personnel Biomarkers - blood Blood Glucose - drug effects Blood Glucose - metabolism Cardiologists - psychology Cardiovascular Diseases - diagnosis Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control Cardiovascular Risk Cardiovascular Safety Clinical Competence Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - mortality GLP-1 receptor agonists Glycated Hemoglobin - metabolism Health Knowledge, Attitudes, Practice Humans Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Novel Antiglycemic Drugs Review Reviews Risk Factors Treatment Outcome Type 2 Diabetes Mellitus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!